This bill has been amended

Bill S1306-2013

Requires that insurance companies provide coverage for surveillance tests for ovarian cancer of certain insured individuals

Requires that insurance companies provide coverage for surveillance tests for ovarian cancer of insured individuals who are deemed to be at risk for ovarian cancer.

Details

Actions

  • Jan 8, 2014: REFERRED TO INSURANCE
  • Jan 9, 2013: REFERRED TO INSURANCE

Memo

BILL NUMBER:S1306

TITLE OF BILL: An act to amend the insurance law, in relation to providing coverage for surveillance tests for ovarian cancer

PURPOSE OR GENERAL IDEA OF BILL: To require insurers to cover surveillance tests for ovarian cancer for female insureds who are at risk for this type of cancer

SUMMARY OF SPECIFIC PROVISIONS: Adds a new paragraph 30 to Subsection (i) of section 3216 of the insurance law. Adds a new paragraph 19 to Subsection (k) of section 3221 of the insurance law. Adds a new subsection (jj) to Section 4303 of the insurance law.

Paragraph 30, paragraph 19 and subsection (jj) all provide that every policy that provides medical, major medical or similar comprehensive type coverage shall provide coverage for surveillance tests for ovarian cancer for an insured who is at risk for ovarian cancer. An insured is deemed to be at risk if: she has a family history of one or more first degree relatives with ovarian cancer; three or more female relatives with breast cancer or nonpolvposis colorectal cancer; she tests positive for BRCA 1 or BRCA 2 mutations. Surveillance tests for ovarian cancer shall mean annual screening for ovarian cancer using: CA-125 serum tumor maker testing; transvaginal ultrasound; and pelvic examination.

JUSTIFICATION: Ovarian cancer gives no warning signs and is very difficult to detect. Early detection through surveillance tests and treatment are the keys to stopping this deadly disease.

PRIOR LEGISLATIVE HISTORY: 2005/06 - A.9840 - Referred to Insurance 2007/08 - A.5931 - Referred to Insurance 2009/10 - A.6475 - Held in Insurance 2011/2012 - S.6604 - Referred to Insurance

FISCAL IMPLICATIONS FOR STATE AND LOCAL GOVERNMENTS: Minimal.

EFFECTIVE DATE: This act shall take effect immediately and shall apply to any policy issued, renewed, or modified after such effective date.


Text

STATE OF NEW YORK ________________________________________________________________________ 1306 2013-2014 Regular Sessions IN SENATE (PREFILED) January 9, 2013 ___________
Introduced by Sen. STAVISKY -- read twice and ordered printed, and when printed to be committed to the Committee on Insurance AN ACT to amend the insurance law, in relation to providing coverage for surveillance tests for ovarian cancer THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. Subsection (i) of section 3216 of the insurance law is amended by adding a new paragraph 30 to read as follows: (30) EVERY POLICY THAT PROVIDES MEDICAL, MAJOR-MEDICAL OR SIMILAR COMPREHENSIVE-TYPE COVERAGE SHALL PROVIDE COVERAGE FOR SURVEILLANCE TESTS FOR OVARIAN CANCER FOR AN INSURED WHO IS AT RISK FOR OVARIAN CANCER. (A) FOR PURPOSES OF THIS SUBSECTION, AN INSURED IS DEEMED TO BE AT RISK IF: (I) SHE HAS A FAMILY HISTORY OF: 1. ONE OR MORE FIRST-DEGREE RELATIVE WITH OVARIAN CANCER; 2. THREE OR MORE FEMALE RELATIVES WITH BREAST CANCER; OR 3. NONPOLYPOSIS COLORECTAL CANCER; OR (II) SHE TESTS POSITIVE FOR BRCA1 OR BRCA2 MUTATIONS. (B) FOR PURPOSES OF THIS SUBSECTION, SURVEILLANCE TESTS FOR OVARIAN CANCER SHALL MEAN ANNUAL SCREENING FOR OVARIAN CANCER USING: (I) CA-125 SERUM TUMOR MARKER TESTING; (II) TRANSVAGINAL ULTRASOUND; AND (III) PELVIC EXAMINATION. S 2. Subsection (k) of section 3221 of the insurance law is amended by adding a new paragraph 19 to read as follows: (19) EVERY GROUP OR BLANKET POLICY DELIVERED OR ISSUED FOR DELIVERY IN THIS STATE WHICH PROVIDES HOSPITAL, SURGICAL OR MEDICAL COVERAGE SHALL INCLUDE COVERAGE FOR SURVEILLANCE TESTS FOR OVARIAN CANCER FOR AN INSURED WHO IS AT RISK FOR OVARIAN CANCER. (A) FOR PURPOSES OF THIS SUBSECTION, AN INSURED IS DEEMED TO BE AT RISK IF:
(I) SHE HAS A FAMILY HISTORY OF: 1. ONE OR MORE FIRST-DEGREE RELATIVE WITH OVARIAN CANCER; 2. THREE OR MORE FEMALE RELATIVES WITH BREAST CANCER; OR 3. NONPOLYPOSIS COLORECTAL CANCER; OR (II) SHE TESTS POSITIVE FOR BRCA1 OR BRCA2 MUTATIONS. (B) FOR PURPOSES OF THIS SUBSECTION, SURVEILLANCE TESTS FOR OVARIAN CANCER SHALL MEAN ANNUAL SCREENING FOR OVARIAN CANCER USING: (I) CA-125 SERUM TUMOR MARKER TESTING; (II) TRANSVAGINAL ULTRASOUND; AND (III) PELVIC EXAMINATION. S 3. Section 4303 of the insurance law is amended by adding a new subsection (jj) to read as follows: (JJ) A HEALTH SERVICE CORPORATION OR MEDICAL EXPENSE INDEMNITY CORPO- RATION WHICH PROVIDES MEDICAL, MAJOR-MEDICAL OR SIMILAR COMPREHENSIVE-TYPE COVERAGE MUST PROVIDE COVERAGE FOR SURVEILLANCE TESTS FOR OVARIAN CANCER FOR AN INSURED WHO IS AT RISK FOR OVARIAN CANCER. (1) FOR PURPOSES OF THIS SUBSECTION, AN INSURED IS DEEMED TO BE AT RISK IF: (A) SHE HAS A FAMILY HISTORY OF: (I) ONE OR MORE FIRST-DEGREE RELATIVE WITH OVARIAN CANCER; (II) THREE OR MORE FEMALE RELATIVES WITH BREAST CANCER; OR (III) NONPOLYPOSIS COLORECTAL CANCER; OR (B) SHE TESTS POSITIVE FOR BRCA1 OR BRCA2 MUTATIONS. (2) FOR PURPOSES OF THIS SUBSECTION, SURVEILLANCE TESTS FOR OVARIAN CANCER SHALL MEAN ANNUAL SCREENING FOR OVARIAN CANCER USING: (A) CA-125 SERUM TUMOR MARKER TESTING; (B) TRANSVAGINAL ULTRASOUND; AND (C) PELVIC EXAMINATION. S 4. This act shall take effect immediately and shall apply to any policy issued, renewed, or modified after such effective date.

Comments

Open Legislation comments facilitate discussion of New York State legislation. All comments are subject to moderation. Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity or hate speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Comment moderation is generally performed Monday through Friday.

By contributing or voting you agree to the Terms of Participation and verify you are over 13.

Discuss!

blog comments powered by Disqus